Lyell Immunopharma Inc.

Dozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation

Despite significant fundraising results to date, Lyell Immunopharma has been stuck in neutral with its own cancer cell therapy efforts, and the firm revealed on 24 October that it is merging with priv

The biopharmaceutical industry has been through a tremendous period of company creation, and even with a drop in financings during 2022 and 2023 from record levels of funding in 2020 and 2021, the las

It’s understandable when a company running on fumes takes action to make its dwindling finances last while fundraising conditions are difficult. But when a company with a long cash runway implements l